December 7, 2023

Kedrion announces an eight-year extension of the distribution agreement with Kamada in the US for KEDRAB®

July 19, 2023

Kedrion confirms its commitment against Rabies infections in the US

June 2, 2021

Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

February 10, 2021

Rabies Treatment Demonstrated as Safe and Effective for Use in Children in First Pediatric Trial

August 19, 2020

Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective


  • Enhanced color packaging for clear identification of 2mL and 10mL dosage options
  • User-friendly vertical barcodes on vials for easier scanning

New KEDRAB packaging, with distinctive vial sizes and colors, designed to reduce chances of error

Over the next several months, you can expect to start receiving KEDRAB® (Rabies Immune Globulin [Human]) with enhanced product packaging, as pictured above. Products with new packaging will be shipped when available, and after distributors' current supplies become depleted. As such, it is likely you may not receive both the new 2mL and 10mL product packaging at the same time.